Radiopharmaceutical Market Set to Grow Over 10% Annually, Reaching $13B by 2032 on Cancer Treatments and Asia Expansion
• Radiopharmaceutical market expected to reach $13.67B by 2032, with 10.2% CAGR from 2023 (reached $5.7B in 2023)
• Recent deals - Lilly acquired Point Bio for $1.4B; Bristol Myers bid $4.1B for RayzeBio
• 50+ radiopharmaceuticals now on market; most treat cancer, with diagnostics holding 67% market share in 2022
• North America accounted for 44% of revenue in 2022 on supportive regulations and tech
• Asia Pacific seen as fastest growing region due to aging population, regulatory changes, improving health infrastructure